Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails

Acadia Pharmaceuticals Inc. (ACAD) shares lost 15% in the after-market hours on Mar 11, after the company announced the failure of its late-stage study evaluating pimavanserin for the treatment of negative symptoms of schizophrenia.In the phase III ADVANCE-2 study, treatment with pimavanserin did not achieve statistical significance in demonstrating improvement over placebo on the study’s primary endpoint of change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score. The NSA- ...